BiOptic
BiOptic runs AI agents that process molecular data, clinical results and economics to rank drug assets. The system checks patents, papers and biotech pipelines to speed up scouting and due diligence. It generates drug candidates and supports licensing and commercialization steps.
Chai Discovery Raises $70M: AI Redefines Antibody and Drug Design
Chai Discovery’s $70M funding ushers in a new era for AI-powered antibody design, promising faster, more successful drug discoveries with its breakthrough Chai-2 model.
Human Trials Begin for AI-Engineered Cancer Therapies: A New Era in Oncology
AI-designed cancer drugs are entering human trials, signaling a major advance in oncology. Discover how artificial intelligence is accelerating cancer drug discovery and what this means for the future of precision medicine.
Manas AI
Manas AI is a drug discovery company that uses artificial intelligence and computational chemistry to accelerate the development of new medicines. The company combines proprietary AI models, advanced molecular docking techniques, and biological expertise to identify promising drug candidates for cancer and rare diseases. Manas AI’s platform generates custom chemical libraries and employs AI filters to rapidly select high-potential therapeutic compounds. Through a partnership with Microsoft, the company leverages cloud computing to perform molecular docking at speeds 100 times faster than traditional methods. Manas AI is currently focused on developing treatments for aggressive cancers, with plans to expand into other disease areas in the future.